U

United Laboratories International Holdings Ltd
HKEX:3933

Watchlist Manager
United Laboratories International Holdings Ltd
HKEX:3933
Watchlist
Price: 12.3 HKD 4.77% Market Closed
Market Cap: 22.3B HKD
Have any thoughts about
United Laboratories International Holdings Ltd?
Write Note

United Laboratories International Holdings Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

United Laboratories International Holdings Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
U
United Laboratories International Holdings Ltd
HKEX:3933
Net Income (Common)
ÂĄ2.9B
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
18%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Net Income (Common)
HK$2.4B
CAGR 3-Years
2%
CAGR 5-Years
21%
CAGR 10-Years
34%
Sino Biopharmaceutical Ltd
HKEX:1177
Net Income (Common)
ÂĄ4.1B
CAGR 3-Years
-26%
CAGR 5-Years
-15%
CAGR 10-Years
16%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Net Income (Common)
ÂĄ917.4m
CAGR 3-Years
-21%
CAGR 5-Years
-10%
CAGR 10-Years
11%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Net Income (Common)
HK$6.5B
CAGR 3-Years
27%
CAGR 5-Years
6%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Net Income (Common)
-$42m
CAGR 3-Years
38%
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

United Laboratories International Holdings Ltd
Glance View

Market Cap
22.3B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
21.2 HKD
Undervaluation 42%
Intrinsic Value
Price
U

See Also

What is United Laboratories International Holdings Ltd's Net Income (Common)?
Net Income (Common)
2.9B CNY

Based on the financial report for Jun 30, 2024, United Laboratories International Holdings Ltd's Net Income (Common) amounts to 2.9B CNY.

What is United Laboratories International Holdings Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
18%

Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for United Laboratories International Holdings Ltd have been 37% over the past three years , 27% over the past five years , and 18% over the past ten years .

Back to Top